Model Uses Gene Signatures to Predict Drugs Most Likely to Cause Birth Defects | GenomeWeb

By Uduak Grace Thomas

A mathematical model developed by researchers in the informatics program at Children's Hospital Boston can predict a drug's teratogenicity, or risk of causing fetal abnormalities, by examining its gene targets. According to the team, the method could be a useful tool to screen new drugs in the preclinical phase of drug development.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.